Teclistamab
- Generic Name
- Teclistamab
- Brand Names
- Tecvayli
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2119595-80-9
- Unique Ingredient Identifier
- 54534MX6Z9
- Background
Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells. Teclistamab consists of an anti-BCMA arm and an anti-CD3 arm connected via two interchain disulfide bonds, allowing the drug to recruit CD3-expressing T cells to B...
- Indication
Teclistamab is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
...
- Associated Conditions
- Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 1572
- Registration Number
- NCT05243797
- Locations
- 🇧🇷
IDOR- Instituto D'or de pesquisa. Av. São Rafael, Salvador, Brazil
🇧🇷Departamento de Oncologia Clínica AC Camargo Cancer Center, São Paulo, Brazil
🇧🇷Hemocentro UNICAMP, Universidade Estadual de Campinas, São Paulo, Brazil
Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)
- Conditions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2022-08-16
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05161598
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 587
- Registration Number
- NCT05083169
- Locations
- 🇺🇸
Emory University - Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸West Penn Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 140
- Registration Number
- NCT04722146
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 40
- Registration Number
- NCT04696809
- Locations
- 🇯🇵
National Hospital Organization Hiroshima-Nishi Medical Center, Otake, Japan
🇯🇵Kameda Medical Center, Chiba, Japan
🇯🇵Ogaki Municipal Hospital, Gifu, Japan
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 228
- Registration Number
- NCT04586426
- Locations
- 🇨🇦
Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇺🇸University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 194
- Registration Number
- NCT04557098
- Locations
- 🇺🇸
Winship Cancer Institute Emory University, Atlanta, Georgia, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇨🇦University Health Network UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 290
- Registration Number
- NCT04108195
- Locations
- 🇨🇦
Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.